AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8026057 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anterior descending coronary artery occlusion
Number of subjects: 244
Study 8026057 — intervention group
Group type: COMPARATOR
Intervention: Right and left circumflex coronary artery occlusion
Number of subjects: 244
Study 8026057 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior AMI
Number of subjects: 244
Study 8026057 — intervention group
Group type: COMPARATOR
Intervention: Inferior/lateral AMI
Number of subjects: 244
Study 12282925 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 66
Study 12282925 — intervention group
Group type: COMPARATOR
Intervention: Lamicel
Number of subjects: 66
Study 12282925 — intervention group
Group type: COMPARATOR
Intervention: Dilapan
Number of subjects: 66
Study 1207633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 2 mg three times daily for 14 days
Number of subjects: 40
Study 1207633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1207633 — intervention group
Group type: EXPERIMENTAL
Intervention: Before treatment
Number of subjects: 40
Study 30514245 — intervention group
Group type: EXPERIMENTAL
Intervention: The Growth Factory (online mindset intervention)
Number of subjects: 120
Study 30514245 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 120
Study 28786978 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) treatment after 3 months of GnRH agonist (Lupron) ovarian suppression for 4 weeks
Number of subjects: 30
Study 28786978 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P4) treatment after 3 months of GnRH agonist (Lupron) ovarian suppression for 4 weeks
Number of subjects: 30
Study 28786978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus E2 treatment
Number of subjects: 30
Study 28786978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus P4 treatment
Number of subjects: 30
Study 28786978 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 addback compared with Lupron in women with PMDD
Number of subjects: 30
Study 26220254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 62
Study 26220254 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 62
Study 26220254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Sirolimus and Cyclosporine A
Number of subjects: 62
Study 23769551 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (n = 101)
Number of subjects: 200
Study 23769551 — intervention group
Group type: COMPARATOR
Intervention: Losartan (n = 99)
Number of subjects: 200
Study 23769551 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 200
Study 23769551 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 200
Study 23769551 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine and Losartan
Number of subjects: 200
Study 21858460 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulating houses
Number of subjects: 1759
Study 21858460 — intervention group
Group type: EXPERIMENTAL
Intervention: Installing more effective heating in insulated houses
Number of subjects: 1759
Study 18931211 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg of 1% lidocaine with 1:200,000 epinephrine (0.5 mug/kg of epinephrine) IV
Number of subjects: 80
Study 18931211 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study 18931211 — intervention group
Group type: COMPARATOR
Intervention: HR and SBP criteria
Number of subjects: 80
Study 16549968 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 0
Study 16549968 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 0
Study 12670779 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 16
Study 12670779 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pre-treatment + formoterol 18 microg
Number of subjects: 16
Study 12670779 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pre-treatment + formoterol 18 microg
Number of subjects: 16
Study 12670779 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treatment + placebo
Number of subjects: 16
Study 11105736 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate olanzapine initiation (olanzapine, 10 mg q.d. for 3 weeks)
Number of subjects: 209
Study 11105736 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise initiation (a sequence of 1 week each on placebo; olanzapine, 5 mg q.d.; and olanzapine, 10 mg q.d.)
Number of subjects: 209
Study 11105736 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of prior antipsychotic drug
Number of subjects: 209
Study 11105736 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of prior antipsychotic drug
Number of subjects: 209
Study 9167809 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of 0.4% dexamethasone plus traditional modalities
Number of subjects: 40
Study 9167809 — intervention group
Group type: COMPARATOR
Intervention: Placebo iontophoresis plus traditional modalities
Number of subjects: 40
Study 8249574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 120
Study 8249574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 120
Study 8249574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3856667 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint adjusted to mean vertical dimension of 4.25 mm
Number of subjects: 60
Study 3856667 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint adjusted to mean vertical dimension of 8.25 mm
Number of subjects: 60
Study 3856667 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint adjusted to 1 mm from occlusal vertical dimension (Control group)
Number of subjects: 60
Study 31439408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrane® (0.02% tropicamide, 0.31% phenylephrine, 1% lidocaine)
Number of subjects: 82
Study 31439408 — intervention group
Group type: COMPARATOR
Intervention: Mydriasert® (0.28mg tropicamide insert and 5.4mg phenylephrine)
Number of subjects: 82
Study 29501215 — intervention group
Group type: EXPERIMENTAL
Intervention: Video version enriched with text hints denoting the SPIKES steps
Number of subjects: 67
Study 29501215 — intervention group
Group type: COMPARATOR
Intervention: Video version
Number of subjects: 67
Study 29501215 — intervention group
Group type: COMPARATOR
Intervention: Text version
Number of subjects: 67
Study 27088471 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling training for 15 days (30 minutes daily for 5 days a week)
Number of subjects: 8
Study 27088471 — intervention group
Group type: COMPARATOR
Intervention: Conventional resistance and aerobic training for 6 weeks
Number of subjects: 8
Study 24379328 — intervention group
Group type: EXPERIMENTAL
Intervention: MARC Patient Simulator instruction for Group 1
Number of subjects: 2
Study 24379328 — intervention group
Group type: COMPARATOR
Intervention: MARC Patient Simulator instruction for Group 2
Number of subjects: 2
Study 24379328 — intervention group
Group type: COMPARATOR
Intervention: MARC Patient Simulator for Group 3 (fourth-year DS) and Group 4 (dentists)
Number of subjects: 2
Study 23921278 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincision intra-aortic balloon pump
Number of subjects: 110
Study 23921278 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 110
Study 20590718 — intervention group
Group type: EXPERIMENTAL
Intervention: Letters and digits
Number of subjects: 0
Study 20590718 — intervention group
Group type: COMPARATOR
Intervention: Symbols
Number of subjects: 0
Study 20590718 — intervention group
Group type: EXPERIMENTAL
Intervention: W-shaped serial position functions for letters and digits
Number of subjects: 0
Study 20590718 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficit size for letters and digits
Number of subjects: 0
Study 20590718 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol-sound mapping
Number of subjects: 0
Study 18377650 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 18377650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 16899362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for the first 7 days, increased by 25 mg each week up to 150 mg
Number of subjects: 55
Study 16899362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for 21 days followed by a 7-day rest period, repeated for 3 cycles
Number of subjects: 55
Study 16899362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily continuously
Number of subjects: 55
Study 14639082 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week peer-led program
Number of subjects: 327
Study 14639082 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 327
Study 11171466 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (listened to words 'banana', 'melon', 'white', 'black')
Number of subjects: 48
Study 11171466 — intervention group
Group type: COMPARATOR
Intervention: Control group (listened to environmental operating room noise)
Number of subjects: 48
Study 11171466 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (younger patients)
Number of subjects: 48
Study 11171466 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (patients with greater anxiety)
Number of subjects: 48
Study 8619941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release metoclopramide (60 mg every 12 h, total of 300 mg in 2.5 days) plus methylprednisolone (M)
Number of subjects: 50
Study 8619941 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methylprednisolone (M)
Number of subjects: 50
Study 1471511 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 70
Study 1471511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3510823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg thrice daily
Number of subjects: 41
Study 3510823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg thrice daily
Number of subjects: 41
Study 3510823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 41
Study 29486097 — intervention group
Group type: EXPERIMENTAL
Intervention: STH+G advertisements
Number of subjects: 3718
Study 29486097 — intervention group
Group type: EXPERIMENTAL
Intervention: LTH+G advertisements
Number of subjects: 3718
Study 29486097 — intervention group
Group type: EXPERIMENTAL
Intervention: STH advertisements
Number of subjects: 3718
Study 29486097 — intervention group
Group type: EXPERIMENTAL
Intervention: LTH advertisements
Number of subjects: 3718
Study 29486097 — intervention group
Group type: COMPARATOR
Intervention: ALC control
Number of subjects: 3718
Study 29486097 — intervention group
Group type: COMPARATOR
Intervention: NON-ALC control
Number of subjects: 3718
Study 27558161 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting microbial larvicide (FourStar controlled release larvicide, 6% by weight Bacillus thuringiensis israelensis and 1% Bacillus sphaerius) applied in treatment clusters for three rounds at 4-month intervals.
Number of subjects: 28
Study 27558161 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control) in the control clusters.
Number of subjects: 28
Study 24902814 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port TEP hernia repair
Number of subjects: 50
Study 24902814 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-port TEP hernia repair
Number of subjects: 50
Study 23327091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care group
Number of subjects: 60
Study 23327091 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 19965693 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer (D-d) at 1 month after anticoagulation suspension
Number of subjects: 355
Study 19965693 — intervention group
Group type: EXPERIMENTAL
Intervention: D-d abnormal at the third month and remained abnormal afterward
Number of subjects: 355
Study 19965693 — intervention group
Group type: EXPERIMENTAL
Intervention: D-d remained normal at the third month and afterward
Number of subjects: 355
Study 17445878 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) processing of unfamiliar two-word novel metaphoric expressions (signal)
Number of subjects: 0
Study 17445878 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) processing of literal expressions (signal)
Number of subjects: 0
Study 17445878 — intervention group
Group type: COMPARATOR
Intervention: Unrelated word pairs (noise)
Number of subjects: 0
Study 16176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with different forms of intersexuality
Number of subjects: 37
Study 16176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with complete androgen insensitivity syndrome (CAIS)
Number of subjects: 37
Study 16176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls affected by congenital adrenal hyperplasia (CAH)
Number of subjects: 37
Study 12843147 — intervention group
Group type: COMPARATOR
Intervention: AC2993 (synthetic exendin-4; exenatide) 0.1 micro g/kg, administered sc twice daily with meals for 5 days
Number of subjects: 37
Study 12843147 — intervention group
Group type: COMPARATOR
Intervention: AC2993 (synthetic exendin-4; exenatide) 0.05, 0.1, or 0.2 micro g/kg, administered as a single dose following an overnight fast
Number of subjects: 37
Study 12843147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10190914 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin and tobramycin (combination therapy)
Number of subjects: 76
Study 10190914 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin alone
Number of subjects: 76
Study 8664453 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 10
Study 8664453 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 10
Study 8664453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin vs Sodium nitroprusside
Number of subjects: 10
Study 2195226 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft posterior chamber lens (IOGEL, Alcon) through a 6.5 mm scleral pocket incision
Number of subjects: 2
Study 2195226 — intervention group
Group type: COMPARATOR
Intervention: IOGEL lens implanted through a 3.5 mm incision using a new instrument
Number of subjects: 2
Study 844932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (single intravenous administration)
Number of subjects: 0
Study 844932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (6 months treatment)
Number of subjects: 0
Study 844932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate
Number of subjects: 0
Study 31825569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with trastuzumab and capecitabine
Number of subjects: 612
Study 31825569 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with trastuzumab and capecitabine
Number of subjects: 612
Study 31237718 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation (ever smoking regularly) based on up to 372 single-nucleotide polymorphisms
Number of subjects: 34217
Study 31237718 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation (ever smoking regularly)
Number of subjects: 34217
Study 28183071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 60
Study 28183071 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily routines)
Number of subjects: 60
Study 25979217 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (PTNS) in Group A (n = 11)
Number of subjects: 20
Study 25979217 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment in Group B (n = 9)
Number of subjects: 20
Study 22555780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (1.5 mmol kg(-1) per day)
Number of subjects: 83
Study 22555780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21833652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg 2 hours preoperatively and 24 hours post-surgery
Number of subjects: 101
Study 21833652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg 12 hours preoperatively and 24 hours post-surgery
Number of subjects: 101
Study 21833652 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (control)
Number of subjects: 101
Study 18191322 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate androgen-deprivation therapy (ADT)
Number of subjects: 939
Study 18191322 — intervention group
Group type: COMPARATOR
Intervention: Deferred androgen-deprivation therapy (ADT)
Number of subjects: 939
Study 16843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate treatment for more than 1.5 years
Number of subjects: 0
Study 16843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated CML patients
Number of subjects: 0
Study 16843101 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12771601 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin with interrupted tube feeds
Number of subjects: 16
Study 12771601 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin with continuous tube feeding
Number of subjects: 16
Study 12771601 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin intravenous administration
Number of subjects: 16
Study 10649150 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg/kg)
Number of subjects: 120
Study 10649150 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (20 microg/kg)
Number of subjects: 120
Study 10649150 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 120
Study 10649150 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 120
Study 9330921 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-counselor helping alliance (HA) measured at 1 and 3 months after admission
Number of subjects: 57
Study 9330921 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors' ratings of HA at 3 months
Number of subjects: 57
Study 9330921 — intervention group
Group type: EXPERIMENTAL
Intervention: HA measures
Number of subjects: 57
Study 9330921 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for urinalysis results in the previous month
Number of subjects: 57
Study 8452114 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72,222
Number of subjects: 24
Study 8452114 — intervention group
Group type: COMPARATOR
Intervention: HDM
Number of subjects: 24
Study 3017797 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 7
Study 3017797 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1 + beta 2‐antagonist)
Number of subjects: 7
Study 3017797 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1‐antagonist)
Number of subjects: 7
Study 3017797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29333872 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoes
Number of subjects: 40
Study 29333872 — intervention group
Group type: COMPARATOR
Intervention: Control (regular shoes)
Number of subjects: 40
Study 27439664 — intervention group
Group type: EXPERIMENTAL
Intervention: 940-nm diode laser
Number of subjects: 20
Study 27439664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma desensitizer
Number of subjects: 20
Study 27439664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 24925122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time reduction in women (0.4 ± 1.2 h per day)
Number of subjects: 285
Study 24925122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 285
Study 24925122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time reduction
Number of subjects: 285
Study 22542213 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day Foley catheterization
Number of subjects: 189
Study 22542213 — intervention group
Group type: COMPARATOR
Intervention: 14-day Foley catheterization
Number of subjects: 189
Study 20543309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program using home tele-monitoring
Number of subjects: 0
Study 18755101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group: yearly program with consultations every 15‐21 days, using a low calorie diet, prescribing physical exercise, changing of habits and health education.
Number of subjects: 169
Study 18755101 — intervention group
Group type: COMPARATOR
Intervention: Control group: low calorie diet, seen 3 times/year.
Number of subjects: 169
Study 18755101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 169
Study 15926182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface stent
Number of subjects: 200
Study 15926182 — intervention group
Group type: COMPARATOR
Intervention: Smooth-surface stent
Number of subjects: 200
Study 12556096 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (3.75 mg every 28 days for 24 weeks)
Number of subjects: 81
Study 12556096 — intervention group
Group type: COMPARATOR
Intervention: Danazol (200 mg three times daily for 24 weeks)
Number of subjects: 81
Study 12556096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study 10516939 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP 579 (150 micrograms/kg)
Number of subjects: 0
Study 10516939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7532254 — intervention group
Group type: EXPERIMENTAL
Intervention: Organs from anti-HCV positive donors
Number of subjects: 103
Study 7532254 — intervention group
Group type: COMPARATOR
Intervention: Organs from anti-HCV negative donors
Number of subjects: 103
Study 2390157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon (1mg)
Number of subjects: 0